The Doorstep to the Temple of Wisdom

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 10, 2011, Pages 1417-1418

  Vogelsang, Georgia ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; NOTE; PERIPHERAL BLOOD STEM CELL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 80053040450     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.08.004     Document Type: Note

References (5)

1. Pidala J., Lee S.J., Quinn G., Jim H., Kim J., Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001 April 11, [Epup ahead of print].
2. Kansu E., Gooley T., Flowers M.E., et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001, 98:3868-3870.
3. Chao N.J., Parker P.M., Niland J.C., et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996, 2:86-92.
4. Kneppers E., van der Holt B., Kersten M.J., et al. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood 2011 June 20, Epub ahead of print].
5. Pidala J., Bloom G.C., Enkemann S., Eschrich S., Lancaster J., Anasetti C. Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:729-738.